We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Read MoreHide Full Article
Shares of NuVasive, Inc. rallied to a new 52-week high of $60.37 on Jul 1, closing a bit lower at $59.97. This represents a strong one-year return of about 26.28%, much better than the S&P 500’s 1.65%.
Currently, NuVasive carries a Zacks Rank #1 (Strong Buy). The stock has a market cap of $2.99 billion and an impressive long-term expected earnings growth rate of 14.76%.
Notably, the company has strong investments in key international markets, solid capital placement and strategic acquisitions.
Looking at the current uptrend, we assume that the market is extremely bullish about NuVasive’s recently entered agreement to acquire Biotronic NeuroNetwork for $98 million in cash. The deal, once closed, will not only boost NuVasive’s spine service business but will also solidify its presence across the U.S. and international markets. Moreover, this transaction is expected to be immediately accretive to its adjusted EPS in 2016 and beyond. This transaction will also help the company achieve its 2016 adjusted margin target of 15.8% with growth in revenue over the long haul.
Meanwhile, we are also looking forward to NuVasive’s latest launch of five new surgical solutions at the 84th American Association of Neurological Surgeons (AANS), advancing its lumbar and cervical spine surgery portfolio.
The company had also announced the U.S. launch of AttraX Putty, a next generation, synthetic bone graft product for use as an autograft extender in posterolateral spine surgery. This addition will further boost the company’s biologics portfolio.
Moreover, the company completed two major acquisitions – Ellipse Technologies and Mega Surgical. The takeovers are expected to boost NuVasive’s revenues by an approximate 14% from 2015 levels.
Meanwhile, in a bid to expand in the growing spine market, NuVasive launched several products last year and have still maintained the trend in 2016 as well. The company’s newly-acquired MAGEC and PRECICE technologies have fortified its international presence, resulting in an operating profit margin expansion of 150 basis points.
The company also has contributions from core direct market including Japan, Australia, New Zealand, the U.K., Italy and Germany, which resulted in business growth of a strong 20.7% at CER. Currently, Nuvasive expects its international business to grow by 38% in 2016, at CER.
Key Picks
Another stock in the sector carrying the same Zacks Rank as NuVasive is GW Pharmaceuticals plc . Meanwhile, Boston Scientific Corporation (BSX - Free Report) and ICU Medical, Inc. (ICUI - Free Report) are other favorably ranked stocks with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Shares of NuVasive, Inc. rallied to a new 52-week high of $60.37 on Jul 1, closing a bit lower at $59.97. This represents a strong one-year return of about 26.28%, much better than the S&P 500’s 1.65%.
Currently, NuVasive carries a Zacks Rank #1 (Strong Buy). The stock has a market cap of $2.99 billion and an impressive long-term expected earnings growth rate of 14.76%.
Notably, the company has strong investments in key international markets, solid capital placement and strategic acquisitions.
Looking at the current uptrend, we assume that the market is extremely bullish about NuVasive’s recently entered agreement to acquire Biotronic NeuroNetwork for $98 million in cash. The deal, once closed, will not only boost NuVasive’s spine service business but will also solidify its presence across the U.S. and international markets. Moreover, this transaction is expected to be immediately accretive to its adjusted EPS in 2016 and beyond. This transaction will also help the company achieve its 2016 adjusted margin target of 15.8% with growth in revenue over the long haul.
Meanwhile, we are also looking forward to NuVasive’s latest launch of five new surgical solutions at the 84th American Association of Neurological Surgeons (AANS), advancing its lumbar and cervical spine surgery portfolio.
The company had also announced the U.S. launch of AttraX Putty, a next generation, synthetic bone graft product for use as an autograft extender in posterolateral spine surgery. This addition will further boost the company’s biologics portfolio.
Moreover, the company completed two major acquisitions – Ellipse Technologies and Mega Surgical. The takeovers are expected to boost NuVasive’s revenues by an approximate 14% from 2015 levels.
Meanwhile, in a bid to expand in the growing spine market, NuVasive launched several products last year and have still maintained the trend in 2016 as well. The company’s newly-acquired MAGEC and PRECICE technologies have fortified its international presence, resulting in an operating profit margin expansion of 150 basis points.
The company also has contributions from core direct market including Japan, Australia, New Zealand, the U.K., Italy and Germany, which resulted in business growth of a strong 20.7% at CER. Currently, Nuvasive expects its international business to grow by 38% in 2016, at CER.
Key Picks
Another stock in the sector carrying the same Zacks Rank as NuVasive is GW Pharmaceuticals plc . Meanwhile, Boston Scientific Corporation (BSX - Free Report) and ICU Medical, Inc. (ICUI - Free Report) are other favorably ranked stocks with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>